• Invest
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Corporate/HUF Trading Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Product Suite
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Equity Screeners
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    SWP Calculator
    CAGR Calculator
    Simple Interest Calculator
    ELSS Calculator
    Step up SIP Calculator
    All Calculators
    Product Suite
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Share Market Today
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Commodities
    Currency
    Futures & Options
    Derivatives
    Margin Trading
    Events
    Budget 2025
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2025
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement
​

Balaxi Pharmaceuticals Ltd's Q3FY25 Quarter Results

Balaxi Pharmaceuticals Ltd's revenue increased 27.3% YoY
  • 11 Feb 2025
  • Balaxi Pharmaceuticals Ltd reported a 5.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 27.3%.
  • Its expenses for the quarter were up by 5.1% QoQ and 48.2% YoY.
  • The net profit increased 16.8% QoQ and decreased 60.6% YoY.
  • The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 1 during Q3FY25.
(₹ crores) Q3FY25 Q2FY25 Q3FY24 QoQ (%) YoY (%)
Total Income
77.23
73.27
60.65
5.4%
27.3%
Total Expenses
71.16
67.70
48.02
5.1%
48.2%
Profit Before Tax
6.07
5.56
14.27
9.2%
-57.5%
Tax
0.71
0.97
0.68
-26.8%
4.4%
Profit After Tax
5.36
4.59
13.59
16.8%
-60.6%
Earnings Per Share
1.00
0.80
13.20
25.0%
-92.4%

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Balaxi Pharmaceuticals Ltd is a well-established company in the pharmaceutical industry. The company specializes in manufacturing and distributing pharmaceutical products, with a focus on generic medicines. Balaxi Pharmaceuticals operates in both domestic and international markets, aiming to provide affordable healthcare solutions. The company is known for its robust distribution network and a diverse portfolio of products. As of the latest updates, there are no specific major developments provided, but the company continues to maintain a strong presence in its sector.

In the third quarter of fiscal year 2025 (Q3FY25), Balaxi Pharmaceuticals Ltd reported a total income of ₹77.23 crores. This represents a sequential quarter-over-quarter (QoQ) increase of 5.4% from ₹73.27 crores in the second quarter of fiscal year 2025 (Q2FY25). On a year-over-year (YoY) basis, the total income grew by 27.3% compared to ₹60.65 crores in the third quarter of fiscal year 2024 (Q3FY24). This growth in revenue indicates the company's strong performance in expanding its income streams over the past year.

The profit before tax for Q3FY25 stood at ₹6.07 crores, marking a 9.2% QoQ increase from ₹5.56 crores in Q2FY25. However, when compared to the same quarter in the previous year (Q3FY24), there is a significant drop of 57.5% from ₹14.27 crores. After accounting for taxes, the profit after tax for Q3FY25 was ₹5.36 crores, which is a 16.8% increase from the previous quarter's ₹4.59 crores but a substantial decrease of 60.6% from ₹13.59 crores in Q3FY24. The earnings per share (EPS) in Q3FY25 was ₹1.00, a 25.0% increase from ₹0.80 in Q2FY25, but a notable decrease of 92.4% from ₹13.20 in Q3FY24.

In Q3FY25, Balaxi Pharmaceuticals Ltd incurred total expenses amounting to ₹71.16 crores, which is a 5.1% increase from ₹67.70 crores in Q2FY25. When compared to Q3FY24, there is a significant rise of 48.2% from ₹48.02 crores. The tax expense for Q3FY25 was ₹0.71 crores, representing a decrease of 26.8% QoQ from ₹0.97 crores in Q2FY25, and a slight increase of 4.4% YoY from ₹0.68 crores in Q3FY24. These metrics show a trend of increasing operational costs over the quarters and years, impacting the company's profitability metrics.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -

​N
​N
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]